cognitive cybersecurity intelligence

News and Analysis

What CVS Stands to Gain by Setting Up Biosimilar Subsidiary Cordavis

Rather than offer several biosimilars of blockbuster immunology drug Humira, CVS Health is planning to sell a cheaper version from its new subsidiary, Cordavis. CVS has said that this move reduces the cost of biosimilars and ensures product availability; however, insiders argue it’s a profit-driven strategy. CVS plans to sell Hyrimoz, the Humira biosimilar from Sandoz, under a Cordavis private label, with plans to launch in Q1 2024.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts